miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer

Abstract

MicroRNAs have been proposed as novel biomarkers for the diagnosis and treatment of many types of cancer. The levels of five candidate microRNAs (miRNAs) (miR-99a-5p, miR-31-5p, miR-138-5p, miR-21-5p, and miR-375-3p) in sera from oral cancer patients and paired tumor and normal tissues were detected by real-time qPCR. The diagnostic power of these miRNAs was analyzed by receiver operating characteristic (ROC) curves. Patient-derived xenograft (PDX) models of oral cancer were established and utilized to verify the potential therapeutic effect of miR-31-5p. Candidate miRNAs were screened from our previous studies and verified in 11 paired oral cancer and adjacent normal tissues. Only serum miR-31-5p levels were significantly different between oral cancer patients and healthy controls and between pre- and postoperative patients. Based on the logistic regression model, this panel of five miRNAs distinguished oral cancer patients from healthy control, with an area under the ROC curve (AUC) of 0.776 (sensitivity = 76.8% and specificity = 73.6%). Furthermore, a miR-31-5p mimic enhanced the proliferation of normal epithelial cells, and antagomiR-31-5p inhibited the proliferation of oral cancer cells in vitro . In vivo , antagomiR-31-5p significantly inhibited tumor growth in oral cancer PDX models. Our findings suggest that circulating miR-31-5p might act as an independent biomarker for oral cancer diagnosis and could serve as a therapeutic target for oral cancer.

<p>Regulations of miR-183-5p and Snail-Mediated Shikonin-Reduced Epithelial-Mesenchymal Transition in Cervical Cancer Cells</p>

“…19,20 Expression of miR-183-5p has been shown to be associated with the growth and progression of cancer through multiple mechanisms. [21][22][23][24] EMT is a major process to regulate cell migration and invasion. Shikonin reversed the EMT in breast cancer cells via upregulating E-cadherin and downregulating Snail expressions.…”

“…19,20 Expressions of miRNAs, such as miR-183-5p, have been shown to be associated with the growth and progression of cancer through multiple mechanisms. [21][22][23][24] The inhibition of miR-183-5p significantly abolished the effects of tripartite motifcontaining protein 65 (TRIM65), a critical regulator of a variety of cellular processes and tumor progression, on autophagy and cisplatin-induced apoptosis suggesting a critical role of miR-183-5p in mediating the TRIM65regulated autophagy and cisplatin resistance in human lung cancer A549/DDP cells. 21 Another study showed that the expression of long non-coding RNA (lncRNA) taurineupregulated gene 1 (TUG1) was increased in cervical cancer tissues, which was correlated with advanced clinical features and poor overall survival in patient with cervical cancer.…”

Nomogram Based on Systemic Immune-Inflammation Index to Predict Survival of Tongue Cancer Patients Who Underwent Cervical Dissection

“…However, the prognosis of patients with TSCC with the same TNM stage is highly variable since it is influenced by a variety of factors (6). Recent reports have suggested that many molecular biomarkers involved in angiogenesis, metastasis, proliferation, and differentiation could be used to improve prognostic precision for TSCC patients (7)(8)(9). However, these expensive laboratory techniques and comprehensive tests are rarely suitable for TSCC patients.…”

Cell-Free microRNAs as Potential Oral Cancer Biomarkers: From Diagnosis to Therapy

“…These authors observed that antagomiR-31-5p significantly delayed the tumor growth of oral cancer patient-derived xenografts. In addition, they found significantly reduced p-AKT levels and increased PTEN levels in antagomiR-31-5p treated xenografts, indicating that miR-31-5p could be a therapeutic target in oral cancer via the PTEN/AKT pathway [61].…”

“…Importantly, miR-187-5p could act as a potential oncogene promoting proliferation, migration, and anchorage-independent colony formation of oral cancer cells. Recently, Lu et al [61] selected a set of five miRNAs (miR-99a-5p, miR-138-5p, miR-375-3p, miR-21-5p, and miR-31-5p) based on previous miRNA profiling studies and analyzed their expression levels in tissue and serum samples. Although only miR-31-5p was significantly upregulated in tissue and serum samples, the serum expression levels of miR-99a-5p, miR-138-5p and miR-375-3p were significantly related to clinical stage.…”